{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:44:47Z","timestamp":1788173087425,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.bcmd.2015.09.002","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T09:35:25Z","timestamp":1442828125000},"page":"415-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease"],"prefix":"10.1016","volume":"55","author":[{"given":"Deborah","family":"Elstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Abrahamov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naama","family":"Arbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagit","family":"Baris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2015.09.002_bb0005","series-title":"Williams Hematology","first-page":"1065","article-title":"Lipid storage diseases","author":"Zimran","year":"2010"},{"key":"10.1016\/j.bcmd.2015.09.002_bb0010","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2014macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0015","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00003086-198803000-00014","article-title":"Total hip arthroplasty in Gaucher's disease. Long-term prognosis","volume":"228","author":"Goldblatt","year":"1988","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0020","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0140-6736(95)91038-7","article-title":"Replacement therapy with imiglucerase for type 1 Gaucher's disease","volume":"345","author":"Zimran","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2015.09.002_bb0025","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","article-title":"Long-term clinical outcomes in type 1 Gaucher disease following 10years of imiglucerase treatment","volume":"36","author":"Weinreb","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1023\/A:1008859420641","article-title":"Quality of life assessment in adults with type 1 Gaucher disease","volume":"8","author":"Masek","year":"1999","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0035","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1371\/journal.pmed.0010021","article-title":"Enzyme replacement in Gaucher disease","volume":"1","author":"Beutler","year":"2004","journal-title":"PLoS Med."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0040","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/qjmed\/91.7.483","article-title":"Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease","volume":"91","author":"Elstein","year":"1998","journal-title":"Q. J. Med."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0045","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V82.4.1107.1107","article-title":"Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients","volume":"82","author":"Zimran","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.09.002_bb0050","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","article-title":"Phase I\/II and extension study of velaglucerase alfa (gene-activated TM human glucocerebrosidase) replacement therapy in adults with type 1 Gaucher disease: 48-month experience","volume":"115","author":"Zimran","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.09.002_bb0055","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ajh.23383","article-title":"Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase","volume":"88","author":"Zimran","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23382","article-title":"Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease","volume":"88","author":"Ben Turkia","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0065","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.23381","article-title":"Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, phase 3 study","volume":"88","author":"Gonzalez","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0070","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ajh.24012","article-title":"Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: long-term data from phase III clinical trials","volume":"90","author":"Hughes","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0075","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bcmd.2014.05.004","volume":"53","author":"Pastores","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0080","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2147\/PPA.S60771","article-title":"Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment","volume":"8","author":"Espanol","year":"2014","journal-title":"Patient Prefer Adher."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0085","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1017\/S0317167100014359","article-title":"Home IVIG for CIDP: a focus on patient centred care","volume":"40","author":"Katzberg","year":"2013","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0090","doi-asserted-by":"crossref","first-page":"330","DOI":"10.12968\/bjon.2006.15.6.20681","article-title":"Intravenous enzyme replacement therapy: better in home or hospital?","volume":"15","author":"Milligan","year":"2006","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0095","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s10545-007-0686-8","volume":"30","author":"Cox-Brinkman","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0100","doi-asserted-by":"crossref","first-page":"653","DOI":"10.12968\/bjon.2008.17.10.29481","article-title":"Home-based infusion therapy for patients with Fabry disease","volume":"17","author":"Cousins","year":"2008","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0105","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ymgme.2009.04.007","article-title":"Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses","volume":"97","author":"Burton","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ymgme.2010.06.011","article-title":"Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II \u2014 data from the Hunter Outcome Survey","volume":"101","author":"Burton","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0115","first-page":"31","article-title":"Home infusion program for Fabry disease: experience with agalsidase alfa in Argentina","volume":"73","author":"Kisinovsky","year":"2013","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.bcmd.2015.09.002_bb0120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1824-7288-39-53","article-title":"Home treatment in paediatric patients with Hunter syndrome: the first Italian experience","volume":"39","author":"Ceravolo","year":"2013","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.bcmd.2015.09.002_bb0125","series-title":"Lysosomal Disease Network WORLD Symposium","article-title":"The need for disease-specific patient-reported outcome measures for lysosomal storage disorders","author":"Elstein","year":"2015"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615001680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615001680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:32:32Z","timestamp":1761049952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979615001680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1079979615001680"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.09.002","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"13,845 home therapy infusions with velaglucerase alfa exemplify safety of velaglucerase alfa and increased compliance to every-other-week intravenous enzyme replacement therapy for Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}